OliVentures, working with scientific advisors from Duke University in Durham, North Carolina, operational and medical partners in Spain, and laboratories in the U.S., has successfully isolated and performed preclinical trials of key olive polyphenols found in extra-virgin olive oil. In laboratory trials, OliVentures’ hydroxytyrosol- and tyrosol-laden patented olive fruit extract, called Trephenol™, in some cases replicated third-party scientific studies that point to the potential health benefits of olive polyphenols.
OliVentures’ first product, PureVida™, is a patent-pending combination of Trephenol™ olive fruit extract, Curcumin C3 Complex® (Sabinsa Corporation), and a custom blend of marine omega-3 fatty acids.
Dr. Michael Morse, OliVentures’ Chief Medical Officer, in conjunction with a medical team in Spain, developed the formulation for PureVida™ based on the company’s preclinical research on Trephenol™ and third-party evidence as to the potential benefits of coupling Trephenol™ with marine omega-3s and high-purity curcumin. The team believes that the formulation has the potential to support the body's response to inflammation
The clinical trial conducted by OliVentures in Spain (with 45 patients) sought to demonstrate that the unique combination of natural ingredients in PureVida™ can lower C-reactive protein (CRP) levels. CRP is a marker of inflammation produced by the liver and other organs in response to the release of certain pro-inflammatory substances by immune cells following injury or infection and other conditions associated with tissue injury and inflammation. The trial results demonstrated reduced levels of CRP and a reduction in joint pain in women taking aromatase inhibitors. Because only one trial, with 45 participants, has been performed (and the results have not yet been peer reviewed), more research is needed to confirm that the results of the one trial are valid.a